Cook SJ - Search Results

1

Reporter cell lines to screen for inhibitors or regulators of the KRAS-RAF-MEK1/2-ERK1/2 pathway.

Weatherdon L, Stuart K, Cassidy M, de la Gándara AM, Okkenhaug H, Muellener M, Mckenzie G, Cook SJ, Gilley R. Weatherdon L, et al. Among authors: cook sj. Biochem J. 2024 Mar 20;481(6):405-422. doi: 10.1042/BCJ20240015. Biochem J. 2024. PMID: 38381045 Free PMC article.

2

Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1.

Squires MS, Nixon PM, Cook SJ. Squires MS, et al. Among authors: cook sj. Biochem J. 2002 Sep 1;366(Pt 2):673-80. doi: 10.1042/BJ20020372. Biochem J. 2002. PMID: 12069688 Free PMC article.

3

Thrombin inhibits Bim (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1.

Chalmers CJ, Balmanno K, Hadfield K, Ley R, Cook SJ. Chalmers CJ, et al. Among authors: cook sj. Biochem J. 2003 Oct 1;375(Pt 1):99-109. doi: 10.1042/BJ20030346. Biochem J. 2003. PMID: 12844349 Free PMC article.

4

The duration of ERK1/2 activity determines the activation of c-Fos and Fra-1 and the composition and quantitative transcriptional output of AP-1.

Chalmers CJ, Gilley R, March HN, Balmanno K, Cook SJ. Chalmers CJ, et al. Among authors: cook sj. Cell Signal. 2007 Apr;19(4):695-704. doi: 10.1016/j.cellsig.2006.09.001. Epub 2006 Sep 15. Cell Signal. 2007. PMID: 17052890

5

ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL.

Ewings KE, Hadfield-Moorhouse K, Wiggins CM, Wickenden JA, Balmanno K, Gilley R, Degenhardt K, White E, Cook SJ. Ewings KE, et al. Among authors: cook sj. EMBO J. 2007 Jun 20;26(12):2856-67. doi: 10.1038/sj.emboj.7601723. Epub 2007 May 24. EMBO J. 2007. PMID: 17525735 Free PMC article.

6

ERK1/2, but not ERK5, is necessary and sufficient for phosphorylation and activation of c-Fos.

Gilley R, March HN, Cook SJ. Gilley R, et al. Among authors: cook sj. Cell Signal. 2009 Jun;21(6):969-77. doi: 10.1016/j.cellsig.2009.02.006. Epub 2009 Feb 25. Cell Signal. 2009. PMID: 19249353

7

CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL.

Gilley R, Lochhead PA, Balmanno K, Oxley D, Clark J, Cook SJ. Gilley R, et al. Among authors: cook sj. Cell Signal. 2012 Jan;24(1):170-80. doi: 10.1016/j.cellsig.2011.08.018. Epub 2011 Sep 8. Cell Signal. 2012. PMID: 21924351

8

Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.

Little AS, Balmanno K, Sale MJ, Smith PD, Cook SJ. Little AS, et al. Among authors: cook sj. Biochem Soc Trans. 2012 Feb;40(1):73-8. doi: 10.1042/BST20110647. Biochem Soc Trans. 2012. PMID: 22260668

9

ERK5 and its role in tumour development.

Lochhead PA, Gilley R, Cook SJ. Lochhead PA, et al. Among authors: cook sj. Biochem Soc Trans. 2012 Feb;40(1):251-6. doi: 10.1042/BST20110663. Biochem Soc Trans. 2012. PMID: 22260700 Review.

10

The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.

Sale MJ, Cook SJ. Sale MJ, et al. Among authors: cook sj. Biochem J. 2013 Mar 1;450(2):285-94. doi: 10.1042/BJ20121212. Biochem J. 2013. PMID: 23234544

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

248 results

Search Page

Filters